MentionFox
Home › Executive changes › Centessa Pharmaceuticals plc
Leadership changes · CNTA · SEC Form 8-K, Item 5.02

Leadership changes at Centessa Pharmaceuticals plc (2026)

Before you join, sell to or invest in Centessa Pharmaceuticals plc

MentionFox check on Centessa Pharmaceuticals plc: no red flags found in 3 sources (checked 14 November 2026). mentionfox.com/c/executive-changes/centessa-pharmaceuticals

Check Centessa Pharmaceuticals plc before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Centessa Pharmaceuticals plc?

Who joined and who left Centessa Pharmaceuticals plc (CNTA)? 3 filings reported from 2026-01-07 to 2026-06-24, each cited to the company's own filing.

As of November 14, 2026, Centessa Pharmaceuticals plc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 7, 2026 to June 24, 2026 (Form 8-K, June 24, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Avoro Capital Advisors LLC also filed stake reports on 18 other companies ↓

Sell to companies like Centessa Pharmaceuticals plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-24
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-13
  • · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-01-07
Changes3
Latest filing2026-06-24

Centessa Pharmaceuticals plc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-07 to 2026-06-24. Every row below is cited to the filing it comes from, and this page adds each new change as Centessa Pharmaceuticals plc files it.

Also on the record for Centessa Pharmaceuticals plc

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G/A, by INDEX VENTURES LIFE VI (JERSEY) L.P.—5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Pentwater Capital Management LP—5%+ stakesSource
August 12, 2026Stake report, Schedule 13G/A, by Adage Capital Management, L.P.—5%+ stakesSource
August 4, 2026Stake report, Schedule 13G/A, by Medicxi Growth I LP—5%+ stakesSource
July 8, 2026Stake report, Schedule 13G/A, by FMR LLC—5%+ stakesSource
June 26, 2026Stake report, Schedule 13D/A, by FARALLON CAPITAL MANAGEMENT, L.L.C.—5%+ stakesSource
June 24, 2026Stake report, Schedule 13D, by FARALLON CAPITAL MANAGEMENT, L.L.C.6.1% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by Pentwater Capital Management LP5.3% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC7.39% of the class5%+ stakesSource
May 13, 2026Stake report, Schedule 13G/A, by Adage Capital Management, L.P.5.77% of the class5%+ stakesSource
May 6, 2026Stake report, Schedule 13G/A, by FMR LLC7.5% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC9.97% of the class5%+ stakesSource

Selling to them or working with them? See who runs Centessa Pharmaceuticals plc now and the warning signs.

Free to see. No signup.

Keep reading

More on Centessa Pharmaceuticals plc and the records around it.

Centessa Pharmaceuticals plc elsewhere on the record

Companies that share a holder

Want the whole picture on Centessa Pharmaceuticals plc?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Centessa Pharmaceuticals plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Centessa Pharmaceuticals plc covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    15 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 20 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-06-24Reportednot named in the filing8-K, 2026-06-24
2026-02-13Reportednot named in the filing8-K, 2026-02-13
2026-01-07Reportednot named in the filing8-K/A, 2026-01-07
Selling to Centessa Pharmaceuticals plc?

New leaders reset buying decisions — get the Full Report on Centessa Pharmaceuticals plc: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Centessa Pharmaceuticals plc

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Centessa Pharmaceuticals plc, with the record behind each one.

Find candidates like senior executive at Centessa Pharmaceuticals plc

Every change, in the filing's words

Filed 2026-06-24 · 8-K

Reported

(Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.

Also stated in this filing

  • Additionally, in connection with the Acquisition and as of the Effective Time, each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa and each committee thereof on which such director served.
  • As of the Effective Time, Christopher Stokes and Kristina Mignon Wright were appointed as directors of the Company.
Filed 2026-02-13 · 8-K

Reported

Pursuant to the Advisory Agreement, Dr. Saha has agreed to provide certain advisory services to the Company for an initial six-month period, automatically continuing thereafter unless terminated by either party, for an hourly advisory fee of $376.00, plus reimbursement of business expenses.

Also stated in this filing

  • As previously disclosed, effective January 1, 2026, Saurabh Saha, M.D., Ph.D., stepped down from his position as Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals plc (the "Company" or "Centessa").
  • In connection with his appointment as advisor to the CEO, on February 9, 2026, the Company entered into an Advisory Agreement (the "Advisory Agreement") and a separation agreement and general release (the "Separation Agreement") with Dr. Saha.
  • These extended benefits are provided in lieu of any other severance payments or noncompetition consideration under prior agreements, and the Separation Agreement, which includes a general release of claims, becomes effective upon expiration of a seven-business-day revocation period following execution.
Filed 2026-01-07 · 8-K/A

Reported

In connection with this appointment, on January 5, 2026, the Company and Dr. Accardi entered into an Employment Agreement (the "Employment Agreement"), effective as of January 1, 2026.

Also stated in this filing

  • Pursuant to the Employment Agreement, Dr. Accardi's base salary is $600,000 and he is eligible to earn a target annual bonus of fifty percent (50%) of his base salary.
  • The Employment Agreement provides that if we terminate Dr. Accardi's employment outside of the one year period following a sale event (as defined in the Centessa Pharmaceuticals plc 2021 Stock Option and Incentive Plan, or the 2021 Plan) without cause, or Dr. Accardi resigns for good reason, Dr. Accardi will receive 12 months' salary continuation.
  • The Employment Agreement provides that if Dr. Accardi's employment is terminated by us other than for cause, or by Dr. Accardi for good reason within the one year period following a sale event, Dr. Accardi will receive a lump sum payment equal to the sum of (A) 18 months of his then-current base salary and (B) 150% of his target bonus for the year of termination.
  • In addition, the Employment Agreement provides that if any payments or benefits received by Dr. Accardi or otherwise would constitute "parachute payments" within the meaning of Section 280G of the Code and be subject to excise taxes imposed by Section 4999 of the Code, such amount will either be delivered in full or reduced so as not to be subject to excise taxation, whichever amount is higher.

Tools for this story

Each opens in a new tab, filled in for Centessa Pharmaceuticals plc. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/centessa-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Centessa Pharmaceuticals plc?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/centessa-pharmaceuticals